ArticleFrontiers in oncology2025
High carbohydrate antigen 19-9 levels indicate poor prognosis in patients with bladder cancer following radical cystectomy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Caveolin-1 is upregulated in gastric cancer and is associated with tumor progression and prognosis in patients.International journal of clinical and experimental pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Our team previously reported that elevated carbohydrate antigen (CA) 19-9 levels are associated with a worse prognosis in upper tract urothelial carcinoma (UTUC). Several studies have reported a correlation between high tumor burden and elevated CA19-9 levels in urothelial carcinomas. However, no studies have specifically examined the association between CA19-9 levels and outcomes of patients with bladder cancer who underwent radical cystectomy. Therefore, we aimed to evaluate the relationship of CA19-9 levels in bladder cancer patients following radical cystectomy. Materials and Methods: Among the 984 patients who underwent radical cystectomy at the Seoul National University Hospital between 1991 and 2022, 564 patients had available preoperative CA19-9 levels. The patients were divided into two groups: a low CA19-9 group (CA19-9 ≤ 37 U/mL) and high CA19-9 group (CA19-9 > 37 U/mL). Demographic parameters as well as preoperative and postoperative findings were compared between these two groups. Recurrence-free survival and overall survival were analyzed using multivariate Cox regression and Kaplan-Meier analyses. Results: Sex distribution, age, body mass index, and underlying diseases (hypertension and diabetes mellitus) were similar between the two groups. The clinical T and N stages were significantly higher in the high CA19-9 group ( Conclusions: A high CA19-9 level is associated with a higher tumor burden in patients with bladder cancer. Furthermore, high CA19-9 levels are correlated to higher pathologic T and N stages after radical cystectomy and worse recurrence-free survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.